Glenn Goddard

Insider Reports History

Entity
Individual
Location
C/O Intellia Therapeutics, Inc, 40 Erie Street, Suite 130, Cambridge, MA
Signature
James Basta, attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Glenn Goddard:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Intellia Therapeutics, Inc. EVP, Chief Financial Officer Common Stock 69.2K $2.03M $29.38 Mar 1, 2024 Direct
Intellia Therapeutics, Inc. EVP, Chief Financial Officer Restricted Stock Unit 3.06K $73.2K $23.90 Jan 1, 2024 Direct
Intellia Therapeutics, Inc. EVP, Chief Financial Officer Stock Option (right to buy) 41.3K Mar 1, 2024 Direct

Insider Reports Filed by Glenn Goddard

Symbol Company Period Transactions Value $ Form Type Date Filed Role
NTLA Intellia Therapeutics, Inc. Mar 1, 2024 2 $0 4 Mar 5, 2024 EVP, Chief Financial Officer
NTLA Intellia Therapeutics, Inc. Jan 3, 2024 1 -$158K 4 Jan 5, 2024 EVP, Chief Financial Officer
NTLA Intellia Therapeutics, Inc. Jan 1, 2024 2 $0 4 Jan 3, 2024 EVP, Chief Financial Officer
NTLA Intellia Therapeutics, Inc. Mar 1, 2023 2 $0 4 Mar 3, 2023 EVP, Chief Financial Officer
NTLA Intellia Therapeutics, Inc. Jan 4, 2023 1 -$90.3K 4 Jan 6, 2023 EVP, Chief Financial Officer
NTLA Intellia Therapeutics, Inc. Jan 1, 2023 2 $0 4 Jan 4, 2023 EVP, Chief Financial Officer
NTLA Intellia Therapeutics, Inc. Mar 1, 2022 1 $0 4/A Mar 4, 2022 EVP, Chief Financial Officer
NTLA Intellia Therapeutics, Inc. Jan 1, 2022 5 -$114K 4 Mar 3, 2022 EVP, Chief Financial Officer
NTLA Intellia Therapeutics, Inc. Sep 7, 2021 3 -$576K 4 Sep 9, 2021 EVP, Chief Financial Officer
NTLA Intellia Therapeutics, Inc. Aug 30, 2021 15 -$4.21M 4 Sep 1, 2021 EVP, Chief Financial Officer
NTLA Intellia Therapeutics, Inc. Aug 5, 2021 5 -$2.64M 4 Aug 6, 2021 EVP, Chief Financial Officer